Weight Loss Jabs Could Halve Risk of Obesity Related Cancers, Study Finds
A groundbreaking study presented at the European Congress on Obesity and published in The Lancet’s eClinicalMedicine reveals that weight-loss injections, specifically GLP-1 receptor agonists like liraglutide, exenatide, and dulaglutide, can nearly halve the risk of obesity-related cancers. The Guardian Key Findings Significant Cancer Risk Reduction:
Discover more